Tasso logo

Tasso

tassoinc.com

Tasso develops and sells self-administered blood collection devices that enable virtually painless, needle-free sample collection for patients. Its technology supports at-home diagnostic testing and aims to improve patient experience and health by making blood collection more convenient and accessible.

Facts

HQ
Seattle, Washington, US
Sectors
Medical Equipment Manufacturing
Founded
2014
Type
Corporation Seattle business license
Employees
99
Registered name
Tasso Inc Seattle business license
Stage
Series B
Members see funding amounts.
.
Founders
Ben Casavant, PhD, Erwin Berthier, PhD

Is this your organization? Claim it

Tasso, Inc. and InnoVero to Provide Athlete-Centric Anti-Doping Blood Collection for 2026 Olympic Winter Games

Tasso, Inc. and InnoVero will supply athlete-centric, secure and minimally painful blood collection technology for anti-doping testing at the 2026 Olympic Winter Games, continuing their partnership after Beijing 2022. The collaboration aims to make sample collection more convenient for athletes while maintaining rigorous, secure testing for clean sport.

Tasso, Inc. obtains Health Canada license and EU approvals to sell Tasso Mini in Canada, Italy, and Spain

Tasso, Inc. received Health Canada licensing and additional EU approvals allowing its Tasso Mini blood collection device to be sold in Canada, Italy, and Spain, expanding availability beyond its existing U.S. FDA 510(k) clearance and CE Marking. The Tasso Mini is designed for gentle, virtually painless sampling for sensitive or repeat-use patients and now matches the international availability of Tasso’s flagship Tasso+® device.

Tasso, Inc. renews SOC 2 Type II certification with unqualified opinion after Prescient Assurance audit

Tasso, Inc. renewed its SOC 2 Type II compliance certification with an unqualified (clean) opinion after an independent audit by Prescient Assurance, affirming its enterprise-level data security across platforms and APIs. The renewal underscores Tasso’s commitment to protecting sensitive patient data for its patient-centric blood collection solutions.

Tasso, Inc. grows in 2023 with Aptar, CardioRenal and UBC partnerships and earns MDSAP certification

Tasso, Inc. reports strong 2023 growth driven by new partnerships (Aptar Digital Health, CardioRenal, United BioSource/UBC) and rising demand for its at‑home, patient‑centric blood collection solutions, positioning the company for expanded use in decentralized clinical trials and home diagnostics. The company also earned MDSAP certification, enabling regulatory access to Australia, Canada, the U.S., and facilitating entry into markets like Brazil and Japan.

People

  • Ben Casavant
    Ben Casavant Co-Founder and Chief Executive Officer
  • Ben Casavant
    Ben Casavant Executive Officer, Director, Promoter, Co-founder
  • Erwin Berthier Co-Founder and Chief Technology Officer

Online